Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer

Lung Cancer

Volumn 88, Issue 1, 2015, Pages 74-79

  Takeda, Masayuki ^a   Okamoto, Isamu ^b   Nakagawa, Kazuhiko ^a  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KYUSHU UNIVERSITY HOSPITAL   (Japan)

Author keywords

Adverse event; Epidermal growth factor receptor; Ethnic difference; Non small cell lung cancer; Pooled analysis; Tyrosine kinase inhibitor

Indexed keywords

AFATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN; QUINAZOLINE DERIVATIVE;

ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL TRIAL (TOPIC); DEATH; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; ETHNICITY; HUMAN; INTERSTITIAL LUNG DISEASE; LIVER TOXICITY; MAJOR CLINICAL STUDY; MUTATION; NON SMALL CELL LUNG CANCER; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEPSIS; SKIN TOXICITY; SPLEEN CYST; TREATMENT RELATED DEATH; CARCINOMA, NON-SMALL-CELL LUNG; DRUG-INDUCED LIVER INJURY; GENETICS; LUNG NEOPLASMS; META ANALYSIS; MORTALITY;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG-INDUCED LIVER INJURY; ERLOTINIB HYDROCHLORIDE; HUMANS; LUNG NEOPLASMS; MUTATION; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84924542122     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2015.01.026     Document Type: Article

References (36)

1. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350:2129-2139.
2. Paez J.G., Janne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304:1497-1500.
3. Mitsudomi T., Morita S., Yatabe Y., Negoro S., Okamoto I., Tsurutani J., et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010, 11:121-128.
4. Maemondo M., Inoue A., Kobayashi K., Sugawara S., Oizumi S., Isobe H., et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010, 362:2380-2388.
5. Zhou C., Wu Y.L., Chen G., Feng J., Liu X.Q., Wang C., et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011, 12:735-742.
6. Rosell R., Carcereny E., Gervais R., Vergnenegre A., Massuti B., Felip E., et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012, 13:239-246.
7. Sequist L.V., Yang J.C., Yamamoto N., O'Byrne K., Hirsh V., Mok T., et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013, 31:3327-3334.
8. Wu Y.L., Zhou C., Hu C.P., Feng J., Lu S., Huang Y., et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol 2014, 15:213-222.
9. Petrelli F., Borgonovo K., Cabiddu M., Barni S. Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non-small-cell lung cancer: a meta-analysis of 13 randomized trials. Clin Lung Cancer 2012, 13:107-114.
10. Paz-Ares L., Soulieres D., Melezinek I., Moecks J., Keil L., Mok T., et al. Clinical outcomes in non-small-cell lung cancer patients with EGFR mutations: pooled analysis. J Cell Mol Med 2010, 14:51-69.
11. Yang J.C., Shih J.Y., Su W.C., Hsia T.C., Tsai C.M., Ou S.H., et al. Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial. Lancet Oncol 2012, 13:539-548.
12. Rosell R., Moran T., Queralt C., Porta R., Cardenal F., Camps C., et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009, 361:958-967.
13. Inoue A., Kobayashi K., Usui K., Maemondo M., Okinaga S., Mikami I., et al. First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. J Clin Oncol 2009, 27:1394-1400.
14. Rosell R., Perez-Roca L., Sanchez J.J., Cobo M., Moran T., Chaib I., et al. Customized treatment in non-small-cell lung cancer based on EGFR mutations and BRCA1 mRNA expression. PLoS ONE 2009, 4:e5133.
15. Asahina H., Yamazaki K., Kinoshita I., Sukoh N., Harada M., Yokouchi H., et al. A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations. Br J Cancer 2006, 95:998-1004.
16. Inoue A., Suzuki T., Fukuhara T., Maemondo M., Kimura Y., Morikawa N., et al. Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations. J Clin Oncol 2006, 24:3340-3346.
17. Sutani A., Nagai Y., Udagawa K., Uchida Y., Koyama N., Murayama Y., et al. Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clamp. Br J Cancer 2006, 95:1483-1489.
18. Sunaga N., Tomizawa Y., Yanagitani N., Iijima H., Kaira K., Shimizu K., et al. Phase II prospective study of the efficacy of gefitinib for the treatment of stage III/IV non-small cell lung cancer with EGFR mutations, irrespective of previous chemotherapy. Lung Cancer 2007, 56:383-389.
19. Yoshida K., Yatabe Y., Park J.Y., Shimizu J., Horio Y., Matsuo K., et al. Prospective validation for prediction of gefitinib sensitivity by epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer. J Thorac Oncol 2007, 2:22-28.
20. Tamura K., Okamoto I., Kashii T., Negoro S., Hirashima T., Kudoh S., et al. Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403). Br J Cancer 2008, 98:907-914.
21. Sequist L.V., Martins R.G., Spigel D., Grunberg S.M., Spira A., Janne P.A., et al. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol 2008, 26:2442-2449.
22. Sugio K., Uramoto H., Onitsuka T., Mizukami M., Ichiki Y., Sugaya M., et al. Prospective phase II study of gefitinib in non-small cell lung cancer with epidermal growth factor receptor gene mutations. Lung Cancer 2009, 64:314-318.
23. Asami K., Koizumi T., Hirai K., Ameshima S., Tsukadaira A., Morozumi N., et al. Gefitinib as first-line treatment in elderly epidermal growth factor receptor-mutated patients with advanced lung adenocarcinoma: results of a Nagano Lung Cancer Research Group study. Clin Lung Cancer 2011, 12:387-392.
24. Maemondo M., Minegishi Y., Inoue A., Kobayashi K., Harada M., Okinaga S., et al. First-line gefitinib in patients aged 75 or older with advanced non-small cell lung cancer harboring epidermal growth factor receptor mutations: NEJ 003 study. J Thorac Oncol 2012, 7:1417-1422.
25. Yamada K., Takayama K., Kawakami S., Saruwatari K., Morinaga R., Harada T., et al. Phase II trial of erlotinib for Japanese patients with previously treated non-small-cell lung cancer harboring EGFR mutations: results of Lung Oncology Group in Kyushu (LOGiK0803). Jpn J Clin Oncol 2013, 43:629-635.
26. Goto K., Nishio M., Yamamoto N., Chikamori K., Hida T., Maemondo M., et al. A prospective, phase II, open-label study (JO22903) of first-line erlotinib in Japanese patients with epidermal growth factor receptor (EGFR) mutation-positive advanced non-small-cell lung cancer (NSCLC). Lung Cancer 2013, 82:109-114.
27. Kim E.S., Hirsh V., Mok T., Socinski M.A., Gervais R., Wu Y.L., et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 2008, 372:1809-1818.
28. Natale R.B., Thongprasert S., Greco F.A., Thomas M., Tsai C.M., Sunpaweravong P., et al. Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol 2011, 29:1059-1066.
29. Kijima T., Shimizu T., Nonen S., Furukawa M., Otani Y., Minami T., et al. Safe and successful treatment with erlotinib after gefitinib-induced hepatotoxicity: difference in metabolism as a possible mechanism. J Clin Oncol 2011, 29:e588-e590.
30. Bradford L.D. CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics 2002, 3:229-243.
31. Liaw Y.F., Brunetto M.R., Hadziyannis S. The natural history of chronic HBV infection and geographical differences. Antivir Ther 2010, 15(Suppl. 3):25-33.
32. Nelson V., Ziehr J., Agulnik M., Johnson M. Afatinib: emerging next-generation tyrosine kinase inhibitor for NSCLC. Onco Targets Ther 2013, 6:135-143.
33. Ando M., Okamoto I., Yamamoto N., Takeda K., Tamura K., Seto T., et al. Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 2006, 24:2549-2556.
34. Kudoh S., Kato H., Nishiwaki Y., Fukuoka M., Nakata K., Ichinose Y., et al. Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study. Am J Respir Crit Care Med 2008, 177:1348-1357.
35. Nakagawa K., Kudoh S., Ohe Y., Johkoh T., Ando M., Yamazaki N., et al. Postmarketing surveillance study of erlotinib in Japanese patients with non-small-cell lung cancer (NSCLC): an interim analysis of 3488 patients (POLARSTAR). J Thorac Oncol 2012, 7:1296-1303.
36. Cohen M.H., Williams G.A., Sridhara R., Chen G., McGuinn W.D., Morse D., et al. United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets. Clin Cancer Res 2004, 10:1212-1218.